Conversely, silencing CTR1 or treatment with TTM significantly reduced glycolytic gene expression and downstream metabolite utilization in HCC cells, thus inhibiting cell survival in hypoxic conditions (142). Here, SLC31A1 is linked to hepatocellular carcinoma.